Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer

Part of paid clinical trials in Huntsville, Alabama.

Sponsor
AstraZeneca
Study ID
NCT01499303
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Fostamatinib — DRUG
    Phase II Trial to evaluate the efficacy of 200mg fostamatinib

Study Details

This study will evaluate the effectiveness of fostamatinib (200 mg twice a day) in patients with worsening or unmanageable lymphoma with a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (abbreviated as DLBCL)

Key Dates

Start date
Dec 31, 2011
Status verified
Aug 2014
Primary completion
Oct 31, 2013
Completion
Oct 31, 2013

Study Design

Enrollment
101 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Fostamatinib 200
    200mg fostamatinib bid n=60

Primary Outcome Measure

Objective Response Rate [ Time Frame: Week 8 ]

Locations (19)

FacilityCityStateZIPSite coordinators
Research SiteHuntsvilleAlabama--
Research SiteDenverColorado--
Research SiteNew HavenConnecticut--
Research SiteSarasotaFlorida--
Research SiteAtlantaGeorgia--
Research SiteIowa CityIowa--
Research SiteBaltimoreMaryland--
Research SiteBostonMassachusetts--
Research SiteRochesterMinnesota--
Research SiteSt LouisMissouri--
Research SiteHackensackNew Jersey--
Research SiteNew YorkNew York--
Research SiteRochesterNew York--
Research SiteColumbusOhio--
Research SiteNashvilleTennessee--
Research SiteHoustonTexas--
Research SiteSan AntonioTexas--
Research SiteCharlottesvilleVirginia--
Research SiteSeattleWashington--

Find similar trials in Huntsville, AL

By research site
Research Site· Huntsville, ALResearch Site· Denver, COResearch Site· New Haven, CTResearch Site· Sarasota, FLResearch Site· Atlanta, GAResearch Site· Iowa City, IA

Related Studies